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Abstract
The concept of pancreatic cancer origin is controversial. Acinar, ductal or islet cells have been
hypothesized as the cell of origin. The pros and cons of each of these hypotheses are discussed.
Based on the world literature and recent observations, pancreatic cells seem to have potential for
phenotypical transdifferentiation, i.e ductal-islet, ductal-acinar, acinar-ductal, acinar-islet, isletacinar and islet-ductal cells. Although the possibility is discussed that cancer may arise from either
islet, ductal or acinar cells, the circumstances favoring the islet cells as the tumor cell origin include
their greater transdifferentiation potency into both pancreatic and extrapancreatic cells, the
presence of a variety of carcinogen-metabolizing enzymes, some of which are present exclusively
in islet cells and the growth factor-rich environment of islets.

Introduction
The complex cellular structure of the pancreas composed
of various exocrine and endocrine cells hampers a clear
understanding of the origin of pancreatic ductal-type adenocarcinoma. During the embryonic development of the
pancreas all exocrine and endocrine cells are derived from
the common precursor cells, the stem cells. It is believed
that these stem cells are retained in the adult pancreas and
are the foundation for cell renewal and tumors; however,
this claim has remained illusive. Recent studies pointing
to the enormous plasticity of each type of pancreatic cell
in changing their phenotype from one type to another
(i.e., transdifferentiation) makes the identification of tumor cell origin more complex. The islet-ductal, acinarductal, ductal-islet cell transdifferentiation in purified cell
populations [1–6] and in vivo [7–10] has been observed.
Consequently, all pancreatic cells could be considered as
a potential facultative stem cell.

There is accumulating evidence that most pancreatic tumors originate from within islets by islet cell transdifferentiation and that pancreatic islet cells play a significant
role in the neoplastic process. There are also observations
that favor that the ductal cells are the source of cancer
cells. To better understand the neoplastic process in the
pancreas, some anatomic-physiological aspects of the tissue should be considered.

Review
Interaction between the exocrine and endocrine cells
It is estimated that the exocrine cells contribute to over
95% (acinar cells 85%, ductal cells 10%) of the volume of
the pancreas, whereas the endocrine cells are believed to
occupy only 1–2% of the pancreatic volume in adults.
Clearly, this estimation is misleading as it does not consider the number of individual cell types. When the size of
the cells is disregarded, the figures would be significantly
different. The circular three-dimensional shape of the islets composed of relatively small, closely packed cells
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causes underestimation of their numbers in histological
sections. Considering the diffuse distribution of the islets,
accounting for about one islet per 1.1 mm2 of the tissue
[11], and the presence of a large number of a single or
small group of islet cells scattered throughout the pancreas and within the ductal epithelium it appears that there
are as many islet cells as acinar cells. The same applies to
ductal cells, as the calculation does not consider the ofteninvisible centroacinar cells that are the components of
ducts. According to our observation, within an acinus
there are as many centroacinar cells as acinar cells. In our
view, centroacinar cells are as multipotential as islet cells
and can give rise to islet cells, acinar cells and tumor cells
[12].
The tight functional and physical interaction between the
endocrine and exocrine cells have been well established
but not sufficiently investigated. The necessary cooperation between the endocrine and exocrine cells well explains the plasticity of the pancreas to adjust to the
internal demands and external stimuli. Hence, each type
of pancreatic cells has the ability to provide a function
that is dictated by the physiological demand in an organized fashion. Islet cells seem to be the frontrunner of the
organization system.
Islet cells, the gatekeeper of the pancreas
The diffuse distribution of islet cells throughout the pancreas either in the form of aggregate (islet) and single or
small group of islets indicate their important function.
They seem to control the flow of pancreatic exocrine and
exocrine function as reflected by their unique ability for
transformation to every pancreatic and some extrapancreatic cell type [1–8]. The controlling effect of islet cells on
the exocrine tissue is also highlighted by the presence of
endocrine cells within the normal, hyperplastic and malignant ductal epithelium, in both humans and animals
[13–17]. Another extremely important function of the islet cells, not similarly shared by other pancreatic cells, is
the defensive strategy provided by drug-metabolizing enzymes. Among the two major groups of drug-metabolizing enzymes in mammals, cytochrome P450 isozymes
(CYP) and glutathione S-transferases (GST) [18–22],
which are known to be involved in the metabolism of a
variety of toxins and carcinogens, were found to be expressed primarily or exclusively in the islet cells of every
species that we have investigated, including humans,
monkeys, pigs, dogs, guinea pigs, rabbits, rats, hamsters
and mouse [19]. This implies a greater involvement of islet cells in the metabolism of xenobiotics within the pancreas. Strikingly, in humans, four of the CYP isozymes
were expressed exclusively in the PP cells, and two isozymes were expressed in a higher concentration in the PP
cells than in the other islet cells [22]. Considering the anatomical blood supply of the pancreas, the primary pres-
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ence of the xenobiotic enzymes in the islets is self
explanatory, as in humans and other mammalian species,
part of the arterial blood passes through the islets before
nourishing the exocrine pancreas [23–27].
Evidence for the derivation of tumors from islet cells
Experimental data
The following observations support the unequivocal role
of !-cells in transdifferentiation and, thus the carcinogenesis process: 1) Experimentally, the first histological alterations are the appearance of intrainsular ductular
structures showing different stages of progression from
normal to malignant pattern. These lesions are initially
confined within the islet boundary and are sharply demarcated from the surrounding tissue (Fig. 1a,1b,1c). 2) The
pretreatment of hamsters with streptozotocin, which selectively destroys !-cells, inhibits the pancreatic tumorigenesis [28]; 3) Genetically diabetic hamsters with
depleted !-cells are resistant to the pancreatic carcinogenic effect of N-nitrosobis(2-oxopropyl)amine (BOP),
whereas the pancreas of a non-diabetic strain with intact
!-cells is not [29]; 4) Stimulation of !-cell neogenesis (nesidioblastosis) enhances pancreatic carcinogenicity of
BOP [30]; 5) Transplantation of homologous islets into
the submandibular gland (a non-target tissue of BOP) of
hamsters and the subsequent BOP treatment of the recipient hamsters results in the development of ductal-type
adenocarcinomas in the areas of transplanted islets
[31,32]. Histological findings point to the development of
malignant glands in the center of islets, the exclusive position of !-cells in hamsters; 6) Malignant transformation
of freshly isolated hamster pancreatic islets by BOP in vitro
[33]. Although the treatment of cultured hamster pancreatic ductal cells also led to the formation of ductal adenocarcinomas [34] these tumors, contrary to those derived
from islet cells [33], did not show the mutation of the cK-ras oncogene [35], the most common genetic abnormality in human pancreatic adenocarcinomas [36,37].
Additionally, only the cultured islets cells treated with
BOP showed an inactivation of the p16 (INK4a) gene (homozygous deletion) [38], which is found in 90–100% of
human pancreatic adenocarcinomas [39]; 7) BOP-treatment of freshly isolated islets containing !-cells, but not
those which were depleted of !-cells, resulted in malignant transformation (unpublished); 8) Isolated human
islets but not human ductal cells treated with BOP could
be grown in serum-free, growth factor-free medium and
showed a mutation of c-Ki-ras (unpublished). In neither
of the in vivo and in vitro studies could we identify cells
which could be regarded as stem cells although more than
50 human and hamster islets were subjected to electron
microscopical examination [1–3]. Considering the rarity
of stem cells among the mature cells, however, (about 1 in
10,000 in bone marrow [40]), we could have missed the
identification of these cells.
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Figure 1
Formation of malignant ductular structures within hamster's islets. a) The lesions is confined to the islets and is sharply demarcated from the surrounding tissue by a layer of fibrosis and inflammatory cells invaded by cancer. H&E × 30. b) Similar lesions
showing irregularly shaped malignant glands replacing the islet. H&E × 30. c) In this lesions most part of islet is replaced by
malignant gland and sclerosis. Note the sharp delineation of the lesions. Local cancer invasion is seen in the lower portion. H&E
× 30. d) An atrophic islet in a patients with chronic pancreatitis. A ductular structure (arrow) is composed of light eosinophilc
and clear cells intermingled with islet cells. H&E × 120. e) Another atrophic human islet far remote of a cancer. A dysplastic
ductular structure (arrow) in the islet without any signs of depression in the surrounding islet cells. H&E × 120. f) An islet in the
vicinity of a well-differentiated adenocarcinoma containing large atypical cells (arrows) intermingled with intact islet cells. H&E ×
72. g) A human islet cell in a patient with pancreatic adenocarcinoma loaded with material immunoreactive with anti-MUC-1
antibody (fine granules). Although in these islets the immunoreactivity with anti-insulin has diminished, some granules show
reactivity with anti-insulin (arrows). × 104,000, h) Normal human islet. One endocrine cell shows a typical cilia identical to
those present in ductal-ductular cells. × 7,200. i) Fine structure of a well-differentiated adenocarcinoma, some cells of which
show a few regular or rudimentary granules of endocrine type (arrow). × 7,200.
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Clinical data
Intrainsular ductular formation and their malignant
counterparts have also been observed in the human pancreas [17,41–43]. Around 70% of pancreatic cancer patients, who clinically have an altered glucose tolerance,
islet cells lose their reactivity to anti-insulin and express
ductal cell markers, including carbohydrate antigen CA19-9, DU-PAN-2 and Tag-72, and develop intrainsular
ductular structures (Fig. 1d,1e) that express the same antigens [42,43]. Moreover, the occurrence of the same antigen in islet cells and in intrainsular ductular cells within
the same islet [42–44] indicates a causal relationship between the altered islet cells and intrainsular ductular cells.
In some islets, single or a group of large atypical cells, suggesting malignant cells (Fig. 1f) can be seen as was also
found in our previous studies [17]. Our electron microscopic examinations have shown that the normal-appearing islet cells within the altered islets contain Muc1 (Fig.
1g), the backbone of these carbohydrate antigens. Moreover single cilia, (Fig. 1h), which is a specialized structure
of ductal/ductular cells [45], can be found in islet cells.
This structure along with other changes observed during
transdifferentiation, indicate that islet cells have the inherent ability to make phenotypical changes and that the
genes involved in the differentiation of different pancreatic cells are closely related. This process is also highlighted
by the presence of endocrine-like granules in some cancer
cells (Fig. 1i.), which can express neuroendocrine cell
makers, including NSE, neuronal adhesion molecule [46]
and !-tubulin (Fig. 2a). The presence of islet cells within
the malignant epithelium, sometimes exceeding the
number of tumor cells [16] is a clear indication that tumor
cells are derived from transdifferentiated islet cells, which
seem to present facultative precursor cells.
Pathophysiological consideration
Islet cells are the major pancreatic cells that are equipped
with a variety of drug-metabolizing enzymes. Based on
the aforementioned insulo-portal blood vessels, xenobiotic first reaches the islets, where it is metabolized to either a non-toxic or a proximate carcinogen. The latter
substances generally react in millisecond with the target
DNA to form adducts required for the neoplastic process,
which triggers the transformation of the affected islet cells
to undifferentiated, intrainsular duct-like cells. One can
argue that because of the lack of or low concentration of
the enzymes, the ductal and acinar cells are exposed to the
carcinogen in a much lesser degree and the damaged DNA
are repaired quickly. As will be discussed below, the presence of only a few cells containing drug-metabolizing enzymes within the ductal epithelium, from which we
believe that ductal cell alteration occurs could explain the
reason for the much later appearance of ductal alteration.
In the islet cells, however, the extent of DNA damage may
exceed the repair capability and the presence of a massive

http://www.molecular-cancer.com/content/2/1/13

amount of growth factors within the islets could trigger
the promotion of the neoplastic process. This may explain
the reason for the initial development of the lesions within the islets. In this context, the expression of CYP2E1 by
PP cells, which are frequently present in a large number
within the ductal epithelium [22], is noteworthy, because
this enzyme is involved in the metabolism of carcinogenic
nitrosamines, some of which are present in tobacco
smoke [47,48], and suggested to present pancreatic carcinogens. Whether or not this peculiar distribution of carcinogen-metabolizing enzymes in PP cells is the reason
for the frequent development of pancreatic cancer in the
head of the pancreas [20], is a hypothetical question.
Evidence for the derivation of tumors from ductal cells
The ductal cell structure of the majority of pancreatic tumors and the ability of ductal cells to proliferate are the
overwhelming reasons to suggest that ductal cells are the
origin of pancreatic adenocarcinomas. The expression of
ductal markers, in cancer cells goes along with this possibility. Indeed, some types of cancer, the intraductal
tumors, seem to arise from ductal cells and remain within
the ductal boundary for a while before invasion. The apparent ability of ductal cells to differentiate into other cell
types, including squamous, mucinous and pyloric cells
further supports the ability of ductal cells to undergo malignant transformation.

One of the landmark studies suggesting histological evidence for ductal cell origin of pancreatic cancer came from
a study of Cubilla and Fitzgerald [49], who studied 227
patients and observed that the incidence of ductal hyperplasias in patients with pancreatic cancer was much greater than in those without cancer. The presence of similar
spatial distribution of lesions in tumors was consistent
with the hypothesis that such lesions might represent incipient pancreatic adenocarcinoma. These findings were
later confirmed by other investigators [50,51]. The only
problem with these studies was that they were done at one
particular stage and hence these findings were arguable in
the sense that whether these pancreatic duct lesions represented the intraductal extension of an invasive cancer or
they themselves are a true precursor to invasive cancer. In
these morphological studies proposing lesions to be the
precursor of infiltrating cancer, there was no direct evidence apart from the morphological unusual growth that
these lesions actually progressed to invasive ductal cancer.
The suggestion of ductal cells as a precursor of cancer cells
is derived mostly from pathomorphological studies. In
one study involving two patients who had atypical papillary duct lesions, it was observed that they developed invasive pancreatic adenocarcinoma a couple of years later
[52]. In another study, [53] three patients developed infiltrating ductal pancreatic adenocarcinoma one and half to
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Figure 2
a) Numerous Helle Zelle (light cells) in hyperplastic ductal epithelium corresponding to PanIN2 (arrows). The cells are small
with light cytoplasm and hyperchromatic round or oval nuclei. Some cells seem to have two nuclei (the second and third arrows
from left). H&E × 120. b) A lesions comparable to PanIN1 to PanIN3 showing clear cells with a small round nuclei surrounded
by a halo (arrow). One of the clear cells (arrowhead) presents two nuclei (post mitotic division?). H&E × 120. c) Electron microscopic findings of a similar lesion. Note several clear cells with one or two nuclei. The cells are poor on cell organelles and lay
between the basal membran and tumor cells. × 7,200. d) Hyperplastic ductules in an elderly man. Several clear cells are seen
within the epithelium. A small group of these cells have interrupted the continuity of the epithelium (bottom arrow) or extended
into the stroma (top arrow). H&E × 120. f) Many of the clear cells that can form a circular layer all along the duct, are immunoreactive with antibodies against islet hormones, especially to anti-glucagon and -chromogranin A and against drug-metabolizing
CYP450 enzymes. ABC method, Anti-glucagon, × 120. f) A large number of endocrine cells reactive with anti-chromogranin A
antibody in a malignant gland. ABC method, × 120. g) A large malignant gland exhibiting papillary infolding of the epithelium. A
remarkably large number of overlapping endocrine cells are present in the basal layer of the malignant epithelium. ABC, combination of anti-insulin and anti-glucagon, 120.
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ten years later after the histological confirmation of atypical papillary ductal lesions in their pancreata. These findings involving morphological observations suggest that
pancreatic ductal hyperplasia is a precursor to pancreatic
cancer. Unlike in breast, skin, colon cervix or prostrate,
which are accessible for non-invasive biopsies, the recognition of an early form of cancer is difficult. The location
of the pancreas, deep in the abdomen and the silent
course of pancreatic cancer makes this approach difficult.
Due to this reason, the described progression of pancreatic ductal lesions to invasive pancreatic cancer is illusive at
best.
On the basis of morphological, clinical, and genetic observations, a progression model for pancreatic ductal adenocarcinoma has been proposed. According to the new
classification of ductal lesions as pancreatic intraductal
neoplasia (PanIN), progression of hyperplasia to malignancy through a series of architectural and cytological
changes have been described [49]. Based on the degree of
cytological and architectural atypia the lesions have been
subclassified into PanIN-1A, PanIN-1B, PanIN-2, and
PanIN-3 [54,55]. In a global sense, PanIN-1A stage epithelial lesions present tall columnar mucin-containing cells
showing slight or no atypia; PanIN-1B designates epithelial lesions that have a papillary, micropapillary, or basally pseudostratified architecture but are otherwise identical
to PanIN-1A. PanIN-2 lesions show moderate atypia including loss of polarity, nuclear crowding, nuclear enlargement,
pseudo-stratification,
and
nuclear
hyperchromatism. PanIN-3 epithelial lesions are usually
papillary or micropapillary with severe atypia.
It is, however, unclear whether these lesions in pancreatic
cancer patients were merely the outgrowth of an invasive
cancer, as shown experimentally [56] and in humans [57],
rather than the precursor themselves. If, as the morphological observations suggest, the duct lesions are de novo
and indeed the precursors to invasive pancreatic cancer,
then the lesions should be clonal and harbor some but
not necessarily all of the mutations and genetic alterations
found in associated infiltrating carcinomas. Moreover, the
incidence of these genetic alterations should increase with
severity of cytological and architectural atypia in duct lesions. Studies, however, show evidence that such lesions
are polyclonal and show heterogeneity in genetic alterations [58]. The presence of a number of genetic alterations
found in pancreatic cancer and in these lesions does not
prove a causal relationship, because, as described above,
there is no evidence that these ductal lesions are the extention of already existing tumors, which are known to be
transferred by pancreatic juice and seed in a location remote from the primary cancer [56,57]. The genes which
have been found to be altered include K-ras, p16, HER2/
Neu, MUC4, DPC4 and BRCA2. Furthermore, the inci-
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dence of these genetic changes increases as the degree of
cytological and architectural atypia in the duct lesions
increases.
Mutations in oncogene K-ras and overexpression of HER2
are supposed to be the early events in the progression of
ductal carcinoma as they have also been reported in ductal
lesions with minimal atypia. K-ras has been found to be
inactivated in about 95% of pancreatic cancer patients
[59]. HER2/Neu is reportedly not overexpressed in normal
ductal epithelium of the pancreas but is said to be overexpressed in almost all duct lesions having significant cytological and architectural atypia [60]. Our own
investigation, however, demonstrated that HER2/Neu is
overexpressed in pancreatic ductal cells in chronic pancreatitis and its expression in cancer cells was strikingly heterogenous and weak [61]. Moreover, the antibodies used
had a greater reactivity with islet and neuroendocrine cells
than with cancer cells [58]. Inactivation of tumor suppressor gene CDKN2A (p16) cyclin dependent kinase inhibitor occurs later and the loss of expression of the p16 gene
could be correlated with the severity of cytological and architectural atypia [62]. Inactivation of CDNK2A, by mutation, deletion or promoter hypermethylation also is a
common event in pancreatic cancer and occurs in about
80–95% of invasive pancreatic adenocarcinomas [63]. A
number of studies have identified common mutational
profiles in simultaneous lesions indicating the relationship between PanINs and the pathogenesis of pancreatic
adenocarcinomas. Although common mutation patterns
in PanIN and associated adenocarcinoma have been observed for K-ras and p16 [64], as stated earlier, the derivation of ductal cell abnormality from original ductal cells
or cancer cells is not clear. It was suggested that alterations
of the p16 gene affect a subset of pancreatic intraductal lesions that contain mutations of the K-ras gene and that
these mutations might identify high-risk precursors of the
invasive malignancy. Loss of other tumor suppressor
genes like p53, BRCA2 and DPC4 (Smad4) occurs later in
neoplasia development. The inactivation of K-ras, however, is not a marker for malignancy because the mutation
can also be found in non-malignant ductal epithelium
[65].
The p53 mutations seem to occur late in PanINs, which
have acquired significant features of dysplasia, reflecting
the function of p53 in preventing malignant progression.
The loss of p53 would result in aberrant genetic instability
which is very much a characteristic of invasive pancreatic
cancer. Mutations in BRCA2 have been primarily associated with familial breast and ovarian cancers but it has also
been observed in approximately 17% of pancreatic cancer
patients having a family history [66]. Normally BRCA2 is
responsible for homologous recombination based DNA
repair and thereby maintaining the genomic stability.
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BRCA2 gets mutated later in the progression of dysplasia
probably because DNA damaging response pathways
might have to be inactivated first (i.e. p53 mutation so
that damages suffered could be tolerated). The MUC4 mucin has also been shown to be one of the characteristic
markers for pancreatic cancer [67]. A recent study on 71
PanIN lesions of different grades and 28 invasive carcinomas shows a steady increase in MUC4 expression along
with the increase in severity of pancreatic duct lesion
[67,68]. Normal pancreatic ducts do not express MUC4.
Increasing expression of MUC4 with an increasing grade
of PanIN supports the assumption of PanIN being a precursor for infiltrating pancreatic ductal adenocarcinoma.
Our unpublished data, however, shows that MUC4 is expressed in ductal cells of chronic pancreatitis. Whether
this finding supports the unspecificity of MUC4 for cancer
or chronic pancreatitis-cancer seuqence, remains to be
seen.
All this information about the progression of genetic abnormality in pancreatic ductal lesions are illusive until a
proof is provided that those lesions are primary alterations. Their association with pancreatic cancer casts doubt
on their primary nature. If they were primary alterations
and show progression, the incidence of pancreatic cancer
multiplicity would be high. The opposite, however, is
true.
The argument that the expression of ductal markers in
ductal adenocarcinoma notwithstanding indicates the
derivation of cancer cells from ductal cells is unsupported.
We have shown that during the transdifferentiation process of islet cells, various markers, including markers for
stem cells (nestin), ductal cells (cytokeratin 7, 19, pancytokeratin, CA 19-9, TAG-72, DU-PAN-2), mesenchymal
cells (vimentin, fibronectin) and others ("-1 antiprotease) are expressed [1–3].

c
Figure 3
a) focal papillary proliferation of the epithelium of the main
pancreatic duct of a hamster. Note the lack of continuity
between the hyperplastic foci. In such lesions, generally a few
or many endocrine cells are present. H&E × 32. b) Part of a
malignant epithelium in a male with pancreatic adenocarcinoma. Note the presence of insulin-positive cells (brown in
color) at the base of papillary configuration of the epithelium.
Mulilabeling with several antibodies against the four islet hormones reveals a larger number of immunoreactive cells. ABC
method, × 120.

The genetic abnormalities also are not convincing evidence as these alterations can occur in cancer cells derived
from transdifferentiated acinar or islet cells. The vital
question that has remained is the cell of origin of ductal
lesions. Are these lesions the result of proliferation and
progression of fully-differentiated ductal cells or by metaplastic conversion of other pancreatic cell types through
emigration and transdifferentiaion [69]?
There are circumstances that argue against the involvement of mature ductal cells in malignancy. It is totally unclear, whether it is ductal cells per se or other cells within
the ductal epithelium with the ability for transdifferentiation and malignancy. It has been suggested that some cells
with stem cell characters reside within ductal epithelium
[70,71]. In histological sections stained with hematoxyllin and eosin we have identified cells, smaller than ductal
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cells with "clear" cytoplasm and round oval hyperchromatic nuclei, which seems to correspond with the "Helle
Zelle" (light cells) described by Feyrter [70] and BonnerWeir [71] in the normal epithelium. A large number if hyperplastic, dysplastic and malignant epithelium, corresponding to PanIN 1–3 (Fig. 2a,2b). Some of these cells
are double nucleated and perhaps represent cell division
(Fig. 2c). Single clear cells can be observed within the epithelium at the level of other ductal cells or as a single cell
or in a small group outside of the ductal basal membrane
and in connection with the basal clear cells (Fig. 2d).
These observations suggest that the clear cells have the potential to form either ductal cells (to produce hyperplastic
epithelium) or endocrine cells. Many, but not all of these
clear cells express endocrine cell markers and the same
drug-metabolizing enzymes as islet cells. (Fig 2e). In some
cases, the number of the endocrine cells nearly exceeds the
number of tumor cells (Figs. 2f and 2g).
Considering the event that ductal cell hyperplasia or dysplasia initially occurs locally and expands gradually (Fig.
3a), and because within the altered epithelium various
number of endocrine cells can be identified (Fig. 3b), it is
reasonable to assume that ductal alterations arise from
clear cells, possibly derived from transdifferentiated endocrine cells. Equally, it is possible that the clear cells are the
precursor of both ductal and endocrine cells. The original
source of these clear cells is also unclear. They are few in
the normal duct, but plenty in hyperplastic ducts. In the
latter case, their random distribution within the epithelium makes their origin from a few preexisting cells unlikely. Their derivation from mature ductal cells by
transdifferentiation is equally hard to accept as mature
ductal cells have a tendency to divide directly without going through an intermediate stage. Whether or not these
clear cells originate from extrapancreatic cells, as described in other tissues [69] is a hypothetical possibility.
Nevertheless, the ability of these cells for the proliferation
and metabolism of various xenobiotics make them the
primary origin of tumors.
Hence, the data on the origin of pancreatic cancer cells
leaves much room for speculation. There is as yet, no definite proof for islet cells or ductal cells as cancer precursor
cells, although the possibility of the involvement of islet
cells is overwhelming. Future molecular biological studies
during cell differentiation in the embryonic and adult tissue could help to understand this presently controversial
issue.
Evidence for the derivation of tumors from acinar cells
Based on the suggested transformation of acinar cells to
duct-like cells, a school of thought considers acinar cells as
the tumor progenitor cells. Evidence, however, is missing.
Although, in the rat model, as well as in humans,
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transdifferentiation of acinar cells to duct-like structures
(pseudoductules) have been reported [70]. The question
whether peudoductules develop from centroacinar cells
or from acinar cells, however, has not been settled. Our
studies have shown that during carcinogenesis centroacinar cells enlarge, form long cytoplasmic extensions that
cover the entire surface of acinar cells, separate acinar cells
from each other and from the basal membrane, hence, by
necrotizing the acinar cells that replaces them [10]. We
have made the same observation in human chronic pancreatitis tissue (unpublished). During this degenerative,
reparative process, some centroacinar cells seem to form
islet cells as endocrine cells are identified within the affected acini [12]. The suggested transdifferentiation of acinar cells to ductular cells in vitro [72,73] does in no way
exclude the role of centroacinar cells in pseudoductular
formation, as generally, centroacinar cells are tightly attached to acinar cells. Presently, however, a transformation of acinar cells to ductular cells can not be entirely
ruled out with certainty. Detailed morphological and molecular biological studies are needed to settle the
controversy. Nevertheless, considering the plasticity of
pancreatic cells, tumor cells can derive from any pancreatic cells.

Conclusion
The overwhelming evidence points to the derivation of
pancreatic cancer from transdifferentiated islet cells within islets and within the ductal epithelium. The remarkable
transdifferentiation tendency of islet cells to a variety of
pancreatic and extrapancreatic cells, found also in both induced and human cancers, the presence of various drugmetabolizing enzymes in all tested species make this cell
the most possible primary tumor origin. The striking
transdifferentiation capability of islet cells into other cell
types also indicates a close functional relationship between the genes that are responsible for the differentiation
toward acinar, ductal and islet cell phenotypes. The
circumstances favoring the origin of cancer cells from islet
cells could well be the environment rich on growth
factors.
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